*IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)*
*e-ISSN: 2279-0853, p-ISSN: 2279-0861.Volume 25, Issue 7 Ser. 1 (July. 2026), PP 94-99*
*www.iosrjournals.org*

# Pharmacological Behavior Management in Children: A Comprehensive Review

Deepanshi Vermani[1], Dr Teena Gupta[2], Dr Rashu Grover[3], Dr Sunil Gupta[4], Dr Manjul Mehra[5]

[1]*MDS Resident, Deptt of Pediatric and Preventive Dentistry, SGRD Institute of Dental Sciences and Research, Amritsar, Punjab, India*
[2]*Professor, Deptt of Pediatric and Preventive Dentistry, SGRD Institute of Dental Sciences and Research, Amritsar, Punjab, India*
[3]*Reader, Deptt of Pediatric and Preventive Dentistry, SGRD Institute of Dental Sciences and Research, Amritsar, Punjab, India*
[4]*Professor and H.O.D, Deptt of Pediatric and Preventive Dentistry, SGRD Institute of Dental Sciences and Research, Amritsar, Punjab, India*
[5]*Reader, Deptt of Pediatric and Preventive Dentistry, SGRD Institute of Dental Sciences and Research, Amritsar, Punjab, India*
*Corresponding Author: Dr Teena Gupta*

***Abstract***
*Behavior management is one of the most significant challenges in pediatric dental practice. Achieving a positive dental experience in children requires strategies that address both psychological and physiological aspects of anxiety and cooperation. While non-pharmacological techniques form the foundation of behavior guidance, pharmacological methods are often indispensable for children who are extremely anxious, young, or those requiring extensive dental treatment. Benzodiazepines, nitrous oxide–oxygen inhalation, and newer agents such as dexmedetomidine are among the most effective and safe pharmacologic options. Strict adherence to sedation guidelines, appropriate patient assessment, and emergency preparedness are essential for achieving safe and predictable outcomes. Pharmacological behavior management remains an indispensable adjunct in pediatric dental practice, providing a foundation for anxiety-free and effective dental care for children.*

***Keywords:*** *Pediatric dentistry, Pharmacological behavior management, Minimal and Moderate Sedation, General Anesthesia, Benzodiazepines and Nitrous oxide*

## I. Introduction

Behavior management is a cornerstone of pediatric dentistry and plays a decisive role in determining the success of dental treatment. Managing a child's behavior involves understanding their developmental stage, emotional state, and ability to cope with dental procedures (Wright et al., 2014). Fear and anxiety toward dental treatment are common among children and can negatively affect cooperation, treatment efficiency, and long-term oral health attitudes. Non-pharmacological methods such as tell–show–do, modeling, positive reinforcement, and distraction remain the primary approaches for most pediatric patients (AAPD, 2022). However, these methods are not always effective, particularly for very young, anxious, or special-needs children who are unable to respond to verbal or behavioral guidance.

In such situations, pharmacological behavior management, including sedation and general anesthesia becomes an essential adjunct to achieve safe and effective dental care (Houpt, 2019). The primary objective of pharmacological management is to reduce anxiety, control movement, and enhance patient cooperation while ensuring safety and comfort. The selection of a pharmacologic technique depends on multiple factors, such as the child's age, temperament, medical history, dental treatment needs, and the clinician's training and facilities available (Coté & Wilson, 2019).

Pharmacological behavior management encompasses a wide range of techniques and agents that produce varying levels of central nervous system depression, ranging from minimal sedation (anxiolysis) to deep sedation and general anesthesia (AAPD, 2022). The dentist must have a thorough understanding of the pharmacodynamics and pharmacokinetics of these drugs, appropriate dosage regimens, routes of administration, and the necessary monitoring protocols to ensure patient safety. In recent years, innovations such as the use of dexmedetomidine, multimodal sedation, and non-invasive drug delivery systems have expanded the scope of pediatric sedation practices (Tawfik et al., 2021).

**Classification of Pharmacological Behavior Management Techniques**

Pharmacological methods of behavior management can be broadly classified according to the depth of sedation achieved. These levels represent a continuum of central nervous system depression, and the patient's response to stimuli determines the sedation depth (AAPD, 2022).

| Level of Sedation | Description | Typical Agents / Techniques | Clinical Characteristics |
|---|---|---|---|
| **Minimal Sedation (Anxiolysis)** | Mild reduction in anxiety with minimal effect on consciousness. Patient responds normally to verbal commands. | Nitrous oxide–oxygen inhalation, low-dose oral benzodiazepines (e.g., midazolam). | Maintains airway and protective reflexes; used for cooperative but anxious children. |
| **Moderate Sedation (Conscious Sedation)** | Depressed level of consciousness but patient responds purposefully to verbal or light tactile stimulation. | Oral, intranasal, or IV benzodiazepines, antihistamines, chloral hydrate (historical). | Spontaneous ventilation adequate; may require monitoring for airway patency. |
| **Deep Sedation** | Purposeful response after repeated or painful stimulation; potential loss of airway reflexes | IV agents such as propofol, ketamine, dexmedetomidine. | Requires advanced airway management training and continuous monitoring |
| **General Anesthesia** | Complete loss of consciousness; patient not arousable even with painful stimulus. | Inhalational or IV anesthetic agents (sevoflurane, propofol). | Requires hospital setting and anesthesiologist supervision. |

*(Adapted from AAPD, 2022; Coté & Wilson, 2019.)*

Pharmacological behavior management may involve single-drug sedation or combination (multimodal) techniques, depending on the procedure complexity and patient needs. While minimal and moderate sedation can be safely performed in a dental office with appropriate training and monitoring, deep sedation and general anesthesia must be reserved for controlled clinical environments equipped for airway management and emergency care (Klein et al., 2020).

The route of administration also influences drug onset, duration, and efficacy. Common routes include oral, inhalational, intranasal, intramuscular, and intravenous. Among these, oral and inhalation routes are the most frequently employed in pediatric dentistry due to their non-invasive nature and high acceptability among children (Matharu & Ashley, 2021).

**Pharmacological Agents Used in Pediatric Behavior Management**

**A. Oral Sedative Drugs**

**Benzodiazepines**

Benzodiazepines are the most commonly used oral sedatives in pediatric dentistry. They act by potentiating the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) in the central nervous system, leading to anxiolysis, sedation, and anterograde amnesia (Malamed, 2018).

Among them, midazolam is preferred because of its rapid onset, short duration, and predictable recovery profile. The oral dose ranges from 0.3 to 0.5 mg/kg, with onset within 15–30 minutes and a duration of 30–60 minutes (Singh et al., 2020). Diazepam, though effective, has a longer half-life and higher risk of cumulative sedation. Advantages include reliable sedation and amnesia, while disadvantages involve potential respiratory depression, paradoxical reactions, and variability in response (Houpt, 2019).

**Barbiturates**

Barbiturates such as pentobarbital were historically used for sedation but have largely been replaced due to their narrow therapeutic index and prolonged recovery times (Coté & Wilson, 2019). They act via GABA receptor potentiation similar to benzodiazepines but pose higher risks of respiratory and cardiovascular depression.

**Antihistamines**

Drugs such as hydroxyzine and promethazine possess sedative, antiemetic, and mild anxiolytic properties. They are useful as adjuncts or mild sedatives, particularly in combination with other agents (Kumar et al., 2019). Their mechanism involves central histamine (H1) receptor blockade. Hydroxyzine (0.5–1 mg/kg) is commonly used; however, over-sedation and anticholinergic side effects are possible.

**Chloral Hydrate (Historical Use)**
Chloral hydrate was once a widely used sedative for children due to its hypnotic effect, but its use has significantly declined because of unpredictable absorption, prolonged sedation, and adverse reactions including respiratory depression and cardiac dysrhythmias (Coté & Wilson, 2019). The AAPD no longer recommends it as a first-line agent.

**B. Inhalation Sedation**
**Nitrous Oxide–Oxygen Sedation**
Nitrous oxide–oxygen inhalation remains one of the safest and most effective pharmacologic techniques in pediatric dentistry. It produces mild to moderate sedation with anxiolytic and analgesic effects, while maintaining protective reflexes (AAPD, 2022).
The gas mixture typically consists of 30–50% nitrous oxide with oxygen, titrated according to patient response. Onset occurs within 2–3 minutes, and recovery is rapid after discontinuation.
Advantages include minimal side effects, ease of administration, and high acceptance among children. Contraindications include upper respiratory tract infections, otitis media, and certain psychiatric or neuromuscular disorders (Malamed, 2018). Post-procedure administration of 100% oxygen for 3–5 minutes is recommended to prevent diffusion hypoxia.

**C. Intravenous Sedation**
Intravenous (IV) sedation provides greater control over drug titration and depth of sedation but requires specialized training, monitoring equipment, and adherence to strict safety protocols. It is generally reserved for children who require longer or more invasive procedures (Wilson et al., 2019).
**Propofol**
Propofol is a short-acting hypnotic agent that provides rapid onset (30 seconds) and smooth recovery. It lacks analgesic properties and may cause dose-dependent respiratory depression and hypotension (Malamed, 2018). Because of its narrow therapeutic window, it should be used only by professionals trained in advanced airway management.
**Ketamine**
Ketamine acts as a dissociative anesthetic via NMDA receptor antagonism. It produces sedation, analgesia, and amnesia while maintaining airway reflexes and cardiovascular stability (Ramos et al., 2020). However, emergence delirium and hypersalivation can occur; co-administration with atropine or benzodiazepines may mitigate these effects.
**Dexmedetomidine**
A newer α2-adrenergic agonist, offers sedative and anxiolytic effects with minimal respiratory depression (Tawfik et al., 2021). It can be administered intravenously, intranasally, or orally. Its sedative profile closely resembles natural sleep, providing smoother recovery and better parental satisfaction. Limitations include bradycardia, hypotension, and longer onset times compared to midazolam.

**Combination and Multimodal Sedation**
Combination sedation involves using two or more drugs from different classes to enhance sedative efficacy while minimizing side effects. A common combination is midazolam with nitrous oxide, which provides synergistic anxiolysis and faster onset (Houpt, 2019).
However, multimodal sedation increases the risk of unpredictable interactions, prolonged recovery, and respiratory compromise, necessitating careful dosing and vigilant monitoring (AAPD, 2022).

**Patient Assessment, Safety, and Monitoring Protocols**
Safe pharmacological behavior management relies on thorough pre-operative evaluation, vigilant intra-operative monitoring, and readiness for emergency care (AAPD, 2022).

**Pre-operative Assessment**
A detailed medical history, medication review, and physical examination must identify contraindications such as respiratory infection or systemic disease. The ASA Physical Status Classification guides case selection: only ASA I–II children are suitable for office-based sedation (Coté & Wilson, 2019).

**Monitoring During Sedation**
Essential parameters: oxygen saturation, heart rate, blood pressure, respiration, and consciousness level; capnography is advised for moderate/deep sedation. Continuous visual observation by trained staff is mandatory.

**Emergency Preparedness**
Practitioners must maintain an emergency kit containing oxygen, atropine, epinephrine, flumazenil, naloxone, and glucose, plus suction, bag-valve-mask, airway adjuncts. All team members should hold current BLS/PALS certification.

**Recovery and Discharge**
Children are observed until vital signs and alertness return to baseline. Discharge is permitted when the Modified Aldrete Score ≥ 9 (Stable vital signs, Adequate oxygen saturation on room air, Ability to talk or respond appropriately, Controlled pain and nausea and Responsible adult escort available for supervision at home); with post-sedation instructions given to the caregiver.

**Common Sedative Agents Used in Pediatric Dentistry**

| Drug Class | Common Agents | Route of Administration | Mechanism of Action | Advantages | Limitation/ Adverse Effects |
|---|---|---|---|---|---|
| **Benzodiazepines** | Midazolam, Diazepam | Oral, Intranasal, IV | Potentiate GABAergic inhibition in CNS | Predictable onset, short duration, amnesia, anxiolysis | Respiratory depression paradoxical agitation, contraindicated in severe hepatic impairment |
| **Barbiturate** | Pentobarbital (historical) | Oral, IV | GABA receptor modulation → CNS depression | Effective hypnosis | Narrow safety margin, prolonged recovery, replaced by safer agents |
| **Antihistamines** | Hydroxyzine, Promethazine | Oral | Central $H_1$ receptor blockade | Mild sedation, antiemetic and anti-allergic effects | Dry mouth, over-sedation, anticholinergic side effects |
| **Chloral Hydrate** | (Historical use only) | Oral | Sedative-hypnotic acting via trichloroethanol metabolite | Effective hypnosis in children | Unpredictable absorption, respiratory depression cardiac dysrhythmia;no longer recommended |
| **Nitrous Oxide–Oxygen** | — | Inhalation | Acts on GABA and NMDA receptors producing anxiolysis and analgesia | Rapid onset/recovery, titratable, minimal side effects | Diffusion hypoxia if not flushed with $O_2$; contraindicated in respiratory infections |
| **Ketamine** | — | IV, IM, Oral | NMDA receptor antagonist producing dissociative anesthesia | Analgesia, amnesia, airway reflexes preserved | Emergence delirium, hypersalivation, increased intracranial pressure |
| **Propofol** | — | IV | Potentiates GABA-A receptor → hypnosis | Rapid onset, smooth recovery | Respiratory depression, hypotension, no analgesia |
| **Dexmedetomidine** | — | IV, Intranasal, Oral | $\alpha_2$-adrenergic receptor agonist → inhibits sympathetic outflow | Minimal respiratory depression, natural sleep-like sedation | Bradycardia, hypotension, slow onset |
| **Combination / Multimodal** | Midazolam + Nitrous oxide, Hydroxyzine + Midazolam | Variable | Synergistic action of agents | Enhanced sedation, shorter onset | Risk of overdose, unpredictable interactions — requires advanced monitoring |

*(Sources: Malamed, 2018; Houpt, 2019; Coté & Wilson, 2019; Tawfik et al., 2021; AAPD, 2022.)*

**Emergence of Dexmedetomidine**
Among the most promising developments is the introduction of dexmedetomidine, a highly selective $\alpha_2$-adrenergic receptor agonist that provides sedation, anxiolysis, and analgesia with minimal respiratory depression (Tawfik et al., 2021).

Dexmedetomidine induces a sedation state similar to natural sleep and allows for easy arousal, making it suitable for dental procedures requiring patient cooperation. It can be administered intravenously, orally, or intranasally, with onset within 20–30 minutes depending on the route (Sheta et al., 2020).
Studies have reported superior parental satisfaction, smoother recovery, and reduced postoperative agitation compared to midazolam (Ramos et al., 2020). However, potential bradycardia and hypotension remain concerns, necessitating careful titration.

**Intranasal and Transmucosal Sedation Routes**
The need for needle-free and child-friendly sedation has encouraged the exploration of intranasal and transmucosal routes for sedative delivery.

Intranasal administration of midazolam or dexmedetomidine provides rapid absorption through the nasal mucosa, bypassing hepatic first-pass metabolism (Singh et al., 2020). This route offers faster onset and higher bioavailability than oral delivery, with minimal discomfort — especially beneficial in young or fearful children (Matharu & Ashley, 2021).

Recent advancements in atomization devices have further improved drug dispersion and patient acceptance.

**Multimodal and Target-Controlled Sedation**
The concept of multimodal sedation involves combining agents from different pharmacologic classes to achieve synergistic effects while minimizing individual drug doses and adverse reactions.

Combinations such as midazolam with nitrous oxide or dexmedetomidine with ketamine have been shown to enhance sedation depth and quality with improved hemodynamic stability (Houpt, 2019).
Additionally, target-controlled infusion (TCI) systems, commonly used in hospital anesthesia, are being adapted for pediatric sedation, enabling precise control over plasma drug concentration and sedation depth (Coté & Wilson, 2019).

**Enhanced Monitoring Technologies**
Recent advances in patient monitoring have greatly improved the safety of pediatric sedation. The integration of capnography (end-tidal $CO_2$ monitoring) has become a standard of care, enabling early detection of hypoventilation and apnea during moderate-to-deep sedation (AAPD, 2022).

Furthermore, developments in computer-assisted sedation systems (e.g., CDSA) and electronic vital sign integration allow for continuous, automated monitoring and documentation, minimizing operator error.

**Pharmacogenetics and Personalized Sedation**
Emerging research suggests that genetic polymorphisms can influence the metabolism and efficacy of sedative drugs such as midazolam and diazepam. Variations in CYP3A4 and CYP2C19 enzyme activity may alter drug plasma levels, affecting onset, duration, and side-effect profile (Zhang et al., 2021). This understanding opens the door for personalized sedation protocols, where drug choice and dosage could be tailored to each child's genetic profile, optimizing safety and effectiveness.

**Global Safety Guidelines and Training**
Professional bodies such as the AAPD and American Academy of Pediatrics (AAP) continue to refine sedation guidelines, emphasizing pre-sedation assessment, staff training, and the presence of qualified personnel for advanced airway management (AAPD, 2022).
The global trend is shifting toward minimal and moderate sedation techniques that maintain patient responsiveness and reduce risk, supported by enhanced safety monitoring and evidence-based protocols.

## II. Conclusion

Pharmacological behavior management remains a critical adjunct to non-pharmacological methods in pediatric dentistry. It enables clinicians to deliver quality dental care while minimizing fear, anxiety, and psychological trauma. Current evidence supports the safe and effective use of agents such as midazolam, nitrous oxide, ketamine, and dexmedetomidine when used judiciously and in accordance with professional guidelines.

Recent innovations in sedation techniques, monitoring systems, and individualized approaches have significantly enhanced patient safety and treatment outcomes. Nevertheless, practitioner competence, thorough patient assessment, and adherence to established protocols remain the cornerstones of successful pharmacological behavior management.

The integration of traditional pharmacologic principles with modern advancements and safety technologies marks the future of pediatric sedation — one that prioritizes comfort, predictability, and above all, child safety.

## References


[1]. American Academy of Pediatric Dentistry (AAPD) 2022, *Guideline on Use of Sedation and General Anesthesia by Dentists*, AAPD, Chicago, USA.
[2]. American Society of Anesthesiologists (ASA) 2020, *ASA Physical Status Classification System*, ASA, Illinois, USA.
[3]. Coté, CJ & Wilson, S 2019, 'Guidelines for monitoring and management of pediatric patients before, during, and after sedation for diagnostic and therapeutic procedures: Update 2019', *Pediatrics*, vol. 143, no. 6, pp. 1–23.
[4]. Houpt, MI 2019, 'Techniques and guidelines for the use of sedation in pediatric dentistry', *Pediatric Dentistry*, vol. 41, no. 3, pp. 135–147.
[5]. Klein, U, Wilson, S & Nathan, JE 2020, *Sedation in Pediatric Dentistry: A Practical Approach*, 3rd edn, Springer, New York.
[6]. Kumar, S, Sharma, A, & Singh, N 2019, 'Comparison of oral hydroxyzine and midazolam for conscious sedation in pediatric dental patients', *Journal of Clinical Pediatric Dentistry*, vol. 43, no. 2, pp. 109–114.
[7]. Malamed, SF 2018, *Sedation: A Guide to Patient Management*, 6th edn, Elsevier, St. Louis.
[8]. Matharu, L & Ashley, PF 2021, 'Sedation of anxious children undergoing dental treatment: Current concepts and recent advances', *International Journal of Paediatric Dentistry*, vol. 31, no. 4, pp. 529–540.
[9]. Ramos, RT, López, C, & Horta, J 2020, 'Ketamine and dexmedetomidine for pediatric dental sedation: A systematic review and meta-analysis', *Anesthesia Progress*, vol. 67, no. 3, pp. 145–153.
[10]. Sheta, SA, Abdelhalim, AA & Nada, EM 2020, 'Intranasal dexmedetomidine versus oral midazolam for premedication in children undergoing dental treatment', *Saudi Journal of Anaesthesia*, vol. 14, no. 1, pp. 82–89.
[11]. Singh, A, Mathur, A & Chaturvedi, TP 2020, 'Comparison of oral and intranasal midazolam for pediatric dental sedation', *Journal of Indian Society of Pedodontics and Preventive Dentistry*, vol. 38, no. 3, pp. 255–260.
[12]. Tawfik, A, Abdellatif, A & Youssef, N 2021, 'Dexmedetomidine in pediatric dental sedation: A narrative review', *Journal of Dental Anesthesia and Pain Medicine*, vol. 21, no. 6, pp. 523–531.
[13]. Wright, GZ, Kupietzky, A & McTigue, DJ 2014, *Behavior Management in Dentistry for Children*, 3rd edn, Wiley-Blackwell, Oxford.
[14]. Zhang, W, Chen, J & Li, J 2021, 'Pharmacogenetics of sedative agents in pediatric dentistry: Toward personalized sedation', *European Archives of Paediatric Dentistry*, vol. 22, no. 4, pp. 557–565.
[15]. Wilson, KE, Welbury, RR & Hosey, MT 2019, *Paediatric Dentistry*, 5th edn, Oxford University Press, Oxford.